Lucia L. C.
- Country
- Spain
- Department
- Hematology
Research Overview
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- Evaluation of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease: A Phase 2 Dose-Ranging Study
- Evaluation of Human Alpha1-Proteinase Inhibitor for Prevention of Acute Graft-Versus-Host Disease in Hematopoietic Cell Transplant Recipients
Data & Insights
Has run more than one trial at 112 of 163 partner sites.
Specializations
Leukemia Research
The investigator specializes in treating B-cell Acute Lymphoblastic Leukemia, with particular focus on resistant and refractory cases. Their work includes innovative cellular therapies like UCART22 and ARI-0001 cells for patients who have failed conventional treatments.
- CD19-positive leukemia treatment
- Cell-based immunotherapy approaches
- Refractory leukemia management
Graft-versus-Host Disease Management
Focused on both acute and chronic forms of graft-versus-host disease, utilizing novel therapeutic agents including belumosudil, axatilimab, and RLS-0071. The research extends to gastrointestinal manifestations of GVHD and microbiome-based treatments.
- Steroid-refractory GVHD treatment
- Novel therapeutic combinations
- Microbiome-based interventions
Lymphoma Studies
Investigates advanced treatments for B-cell lymphoma, particularly focusing on cellular immunotherapy approaches. The research includes innovative T-lymphocyte modification techniques and chimeric antigen receptor development.
- Autologous T-cell therapy
- CAR-T cell development
- Refractory lymphoma treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.